Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Quantumscape Corp (QS) Price & Performance

Heron Therapeutics IncTrade
Quantumscape CorpTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Quantumscape Corp — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Quantumscape Corp trades at $6.06 (market cap $3.62B). The key difference: Quantumscape Corp is far larger — about 39.6× Heron Therapeutics Inc's market cap. Which is the better fit depends on your goals.

HRTXQS
Market Cap
$91.46M$3.62B
Sector
HealthConsumer Cyclical
52-Week High
$1.96$18.44
52-Week Low
$0.39$5.86
Enterprise Value
$189.36M$2.79B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.

Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.

Quantumscape Corp

QuantumScape (QS) trades at $5.91, up 0.85% today, amid a bearish technical trend and negative profitability. The company reported a net loss of $435.05 million in 2025, with cash flow sustained by financing activities. Recent news highlights a joint research agreement with Honda, sparking investor interest in its solid-state battery technology.

The outlook remains speculative, hinging on successful commercialization of its battery technology. Key risks include persistent losses, high cash burn, and competitive pressures. Analyst sentiment is cautious, with no buy ratings and 72.7% hold recommendations, reflecting skepticism about near-term profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About Quantumscape Corp

QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.

Read more on QS